Leukemia, Myeloid, Chronic-Phase × Cytarabine × Clear all Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Phase 3 Completed
744 enrolled
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
Phase 2 Withdrawn
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Phase 3 Completed
1,551 enrolled
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Phase 2 Completed
48 enrolled 12 charts
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
24 enrolled 6 charts
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
Phase 2 Completed
31 enrolled
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
Phase 1 Completed
76 enrolled
Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Phase 3 Unknown
800 enrolled
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
Phase 3 Unknown
1,000 enrolled
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
Phase 1/2 Unknown
60 enrolled
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Phase 3 Unknown
750 enrolled
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 2 Completed
34 enrolled 16 charts
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia
Phase 2 Completed
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Phase 3 Completed
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Phase 1/2 Withdrawn
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
Phase 2 Completed
53 enrolled
Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Phase 2 Completed
90 enrolled
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
Phase 1 Completed
20 enrolled
Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma
Phase 2/3 Completed
19 enrolled